Minimal Residual Disease Testing for Cancer

Effective 1 de agosto, 2024, the medical criteria used to determine medical necessity for the following tests will be simplified: Guardant Reveal and Guardant Response. For additional details related this policy, please click here. 

Gene Expression Profiling for Cutaneous Melanoma

Effective 1 de julho, 2024, prior authorization is being removed from CPT code 0089U for Medicare Advantage plans and commercial products. The service is being changed to a covered service. For additional details related to this policy, please click here.    

Miscellaneous Vascular Embolization Procedures 

Effective 1 de agosto, 2024, hemorrhoidal embolization (HydroPearl microspheres) will not be covered for Medicare Advantage plans and not medically necessary for commercial products. For additional details related this policy, please click here.